Cytori Cell Research Institute,Inc. Logo

Cytori Cell Research Institute,Inc.

Develops devices and cell therapies using a patient's fat tissue to repair injury and treat disease.

3750 | T

Overview

Corporate Details

ISIN(s):
JP3426500009
LEI:
Country:
Japan
Address:
千代田区麹町2丁目3番3号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cytori Cell Research Institute, Inc., now operating as ADR120S, Inc., is a regenerative medicine company focused on developing novel cell therapies. The company engages in the research, development, production, and sale of medical devices and related kits for cell-based treatments. Its core technology centers on a proprietary system to extract and concentrate adipose-derived regenerative cells (ADRCs) from a patient's own fat tissue. These therapies are designed to repair injured tissue, preserve function, and address various diseases with unmet medical needs, such as osteoarthritis and diabetic foot lesions. The company aims to provide safe and effective treatment options by harnessing the potential of cellular therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-14 08:04
Registration Form
確認書
Japanese 8.6 KB
2025-11-14 08:03
Interim / Quarterly Report
半期報告書-第22期(2025/04/01-2026/03/31)
Japanese 194.2 KB
2025-11-07 07:42
Registration Form
確認書
Japanese 8.3 KB
2025-11-07 07:39
Annual Report
訂正有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 597.9 KB
2025-07-01 04:31
AGM Information
臨時報告書
Japanese 24.3 KB
2025-06-27 09:17
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 09:16
Annual Report
有価証券報告書-第21期(2024/04/01-2025/03/31)
Japanese 946.5 KB
2025-06-27 09:16
Governance Information
内部統制報告書-第21期(2024/04/01-2025/03/31)
Japanese 23.7 KB
2025-05-30 02:01
Regulatory Filings
臨時報告書
Japanese 20.1 KB
2025-02-10 08:41
AGM Information
臨時報告書
Japanese 20.5 KB
2025-01-06 08:19
Regulatory Filings
臨時報告書
Japanese 19.0 KB
2024-11-14 08:06
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 08:05
Interim / Quarterly Report
半期報告書-第21期(2024/04/01-2025/03/31)
Japanese 190.1 KB
2024-09-24 09:07
M&A Activity
臨時報告書
Japanese 19.8 KB
2024-07-29 08:30
Major Shareholding Notification
臨時報告書
Japanese 21.5 KB

Automate Your Workflow. Get a real-time feed of all Cytori Cell Research Institute,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cytori Cell Research Institute,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cytori Cell Research Institute,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

NOVAVAX INC Logo
Develops and commercializes nanoparticle vaccines for serious infectious diseases.
United States of America
NVAX
Develops first-in-class drugs and supplements for metabolic and fibrotic diseases.
South Korea
229500
Novo Nordisk Logo
Develops medicines and devices for chronic diseases like diabetes, obesity, and rare disorders.
Denmark
NOVO
NRX Pharmaceuticals, Inc. Logo
Develops novel oral drugs for CNS disorders, targeting suicidal depression and PTSD.
United States of America
NRXP
NuCana plc Logo
Develops safer anti-cancer medicines with ProTide technology to overcome cell resistance.
United States of America
NCNA
NUTEX Investments Plc Logo
Develops & distributes health, cosmetic & pharma products from natural ingredients globally.
Hungary
NUTEX
NutriBand Inc. Logo
Develops abuse-deterrent transdermal patches to make potent drug delivery safer.
United States of America
NTRB
Nuvalent, Inc. Logo
Designs targeted small molecule drugs for kinase-driven cancers to overcome treatment resistance.
United States of America
NUVL
Nuvation Bio Inc. Logo
A clinical-stage biopharma developing novel drugs for difficult-to-treat cancers.
United States of America
NUVB
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT

Talk to a Data Expert

Have a question? We'll get back to you promptly.